In this article, we will discuss Ramucirumab (13). So, let’s get started.
Arterial Thromboembolic Events
Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia occurred in clinical trials including 1.7% of 236 patients who received Ramucirumab as a single agent for gastric cancer in clinical studies. Permanently discontinue Ramucirumab in patients who experience a severe ATE.